ALL FDA approved MS Treatments, Adherence, Compliance, MS Relapse and Mobility
Click here to receive MS news via e-mail Educational presentation provided by MS Views and News …
Teva to Present Pipeline Data on MS Treatments at Ongoing AAN Annual Meeting
Click here to receive MS news via e-mail Teva Pharmaceutical Industries, Ltd., announced that new data on four of its…
Stuart Schlossman
Natalizumab (Tysabri) Targets Molecule Crucial for Type of B-Cell to Accumulate in the Brain
Tysabri Tysabri Mice…
Stuart Schlossman
Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients
− Strong and Sustained Efficacy of TECFIDERA® Supported by Clinical Data and Real-World Evidence – − New ZINBRYTA™ Data Show Impact…
Stuart Schlossman
Genentech to Present New Data at AAN Showing Superior Efficacy of Investigational Medicine Ocrelizumab Versus Comparators on Disease Activity and Progression in Two Forms of Multiple Sclerosis
New analyses showing superior efficacy of ocrelizumab across clinical and subclinical outcomes compared with interferon beta- 1a (Rebif®) in people…
Stuart Schlossman
Case Ties Alemtuzumab to Nocardia Brain Infection
Female patient had history of anorexia, which may have contributed A patient developed a cerebral Nocardia infection while taking the…
Stuart Schlossman
New drug for severe form of MS generates glimmer of hope — and tempered expectations
DR. W. CRUM/TIM BEDDOW/ SCIENCE SOURCE— MRI brain scan from a patient with multiple sclerosis. By DAVID NATHER @DavidNather FEBRUARY 19, 2016…
Stuart Schlossman
Promising Data on ZINBRYTA (Daclizumab High-Yield Process) Compared to Interferon Beta-1a in RRMS
Lead scientists representing Biogen and AbbVie presented new data on clinical results from the Phase 3 study DECIDE on the…
Stuart Schlossman
Lemtrada Update
February 2016 Researchers have found that changes in the composition of immune molecules — specifically, a shift to more anti-inflammatory cytokines…
Stuart Schlossman
Study Shows That People with MS Taking Natalizumab Develop Antibodies to the JC Virus at Higher Than Normal Rates, Emphasizing Need for Regular Monitoring
January 27, 2016 A study by researchers in Germany and France observed changes in JC virus antibody status in two…
Stuart Schlossman
